The Balthasar Laboratory is located
on the fourth floor of Kapoor Hall, on the South Campus of the
University at Buffalo. The University at Buffalo is New York
State's premier public center for graduate and professional
education, as well as the state's largest and most comprehensive
public university.
The Balthasar Laboratory utilizes pharmacokinetic and
pharmacodynamic modeling and simulation to guide the development
of new immunotherapies for the treatment of autoimmunity and
cancer.
Areas of research include
Development of antibody conjugates for targeted, intra-cellular delivery of macromolecular toxins
Engineering monoclonal antibodies for improved pharmacokinetic properties
Investigation of sources of inter-individual variability in monoclonal antibody pharmacokinetics
Investigation of strategies to overcome
the "binding site barrier" to antibody distribution in solid
tumors
Development of improved mathematical
models for predicting the disposition and effects of
monoclonal antibody drugs
Development of new targeting strategies
to optimize the safety and efficacy of intraperitoneal
chemotherapy of ovarian cancers (CA118213)
Development of FcRn inhibitors for
treatment of humoral autoimmune diseases (e.g., myasthenia
gravis, autoimmune neutropenia) (AI60687)
Development of new strategies to treat
immune thrombocytopenic purpura (HL67347)
Investigation of the role of FcRn in the
absorption, distribution, and elimination of IgG antibodies